A data-mining exercise of publicly available mass spectrometry-based proteomics datasets carried out in the dbDEPC database [39] found that certain cohorts of patients for various cancer-types have a tendency to show down-regulation of CRT protein expression i.e. tumoural CRTlow (between 0.20–0.60 fold less expression than corresponding normal tissue in case of thyroid cancer, hepatocellular cancer and breast cancer) (Fig. 5B). This evidence concerns the gene CALR and hepatocellular carcinoma.